These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
173 related articles for article (PubMed ID: 32649325)
1. Factors Associated With Long-Term Use of Percutaneous Tibial Nerve Stimulation for Management of Overactive Bladder Syndrome. Gordon T; Merchant M; Ramm O; Patel M Female Pelvic Med Reconstr Surg; 2021 Jul; 27(7):444-449. PubMed ID: 32649325 [TBL] [Abstract][Full Text] [Related]
2. Subjective and objective responses to PTNS and predictors for success: a retrospective cohort study of percutaneous tibial nerve stimulation for overactive bladder. Iyer S; Laus K; Rugino A; Botros C; Lozo S; Botros SM; Goldberg R; Tomezsko J; Gafni-Kane A; Wroblewski K; Sand P Int Urogynecol J; 2019 Aug; 30(8):1253-1259. PubMed ID: 30467763 [TBL] [Abstract][Full Text] [Related]
3. Factors influencing return for maintenance treatment with percutaneous tibial nerve stimulation for the management of the overactive bladder. Salatzki J; Liechti MD; Spanudakis E; Gonzales G; Baldwin J; Haslam C; Pakzad M; Panicker JN BJU Int; 2019 May; 123(5A):E20-E28. PubMed ID: 30552801 [TBL] [Abstract][Full Text] [Related]
4. Shifts in patient preference of third-line overactive bladder therapy after introduction of the implantable tibial nerve stimulator. Kapur A; Aalami Harandi A; Hartman-Kenzler J; Kim J Neurourol Urodyn; 2024 Apr; 43(4):959-966. PubMed ID: 38390786 [TBL] [Abstract][Full Text] [Related]
5. Persistence in Percutaneous Tibial Nerve Stimulation Treatment for Overactive Bladder Syndrome is Best Predicted by Patient Global Impression of Improvement Rather Than Symptom-Specific Improvement. Brandon C; Oh C; Brucker BM; Rosenblum N; Ferrante KL; Smilen SW; Nitti VW; Pape DM Urology; 2021 Feb; 148():93-99. PubMed ID: 33358753 [TBL] [Abstract][Full Text] [Related]
6. Predictors of successful percutaneous tibial nerve stimulation (PTNS) in the treatment of overactive bladder syndrome. Rostaminia G; Chang C; Pincus JB; Sand PK; Goldberg RP Int Urogynecol J; 2019 Oct; 30(10):1735-1745. PubMed ID: 30498931 [TBL] [Abstract][Full Text] [Related]
7. Long-term real-life adherence of percutaneous tibial nerve stimulation in over 400 patients. Te Dorsthorst MJ; Heesakkers JPFA; van Balken MR Neurourol Urodyn; 2020 Feb; 39(2):702-706. PubMed ID: 31845404 [TBL] [Abstract][Full Text] [Related]
8. A single-blind, randomized controlled trial to evaluate the effectiveness of transcutaneous tibial nerve stimulation (TTNS) in Overactive Bladder symptoms in women responders to percutaneous tibial nerve stimulation (PTNS). Martin-Garcia M; Crampton J Physiotherapy; 2019 Dec; 105(4):469-475. PubMed ID: 30862384 [TBL] [Abstract][Full Text] [Related]
10. Factors associated with overactive bladder symptom improvement after 1 year of monthly percutaneous tibial nerve stimulation therapy. Pincus J; Rostaminia G; Chang C; Gafni-Kane A; Goldberg RP Neurourol Urodyn; 2019 Aug; 38(6):1676-1684. PubMed ID: 31107570 [TBL] [Abstract][Full Text] [Related]
11. Efficacy of percutaneous and transcutaneous tibial nerve stimulation in women with idiopathic overactive bladder: A prospective randomised controlled trial. Sonmez R; Yildiz N; Alkan H Ann Phys Rehabil Med; 2022 Jan; 65(1):101486. PubMed ID: 33429090 [TBL] [Abstract][Full Text] [Related]
12. Patient-reported outcomes in the setting of a randomized control trial on the efficacy of transcutaneous stimulation of the posterior tibial nerve compared to percutaneous stimulation in idiopathic overactive bladder syndrome. Ramírez-García I; Kauffmann S; Blanco-Ratto L; Carralero-Martínez A; Sánchez E Neurourol Urodyn; 2021 Jan; 40(1):295-302. PubMed ID: 33118624 [TBL] [Abstract][Full Text] [Related]
14. Percutaneous Tibial Nerve Stimulation in the Office Setting: Real-world Experience of Over 100 Patients. Sirls ER; Killinger KA; Boura JA; Peters KM Urology; 2018 Mar; 113():34-39. PubMed ID: 29196071 [TBL] [Abstract][Full Text] [Related]
15. Contemporary Patterns of Third-line Treatments for Privately Insured Individuals With Overactive Bladder in the United States. Jiang J; Patil D; Traore EJ; Hammett J; Filson CP Urology; 2020 Aug; 142():87-93. PubMed ID: 32437771 [TBL] [Abstract][Full Text] [Related]
16. Percutaneous tibial nerve stimulation versus sham efficacy in the treatment of refractory overactive bladder: outcomes following a shortened 6-week protocol, a prospective randomized controlled trial. Lashin AM; Eltabey NA; Wadie BS Int Urol Nephrol; 2021 Dec; 53(12):2459-2467. PubMed ID: 34601705 [TBL] [Abstract][Full Text] [Related]
17. Effectiveness and durability of solifenacin versus percutaneous tibial nerve stimulation versus their combination for the treatment of women with overactive bladder syndrome: a randomized controlled study with a follow-up of ten months. Vecchioli-Scaldazza C; Morosetti C Int Braz J Urol; 2018; 44(1):102-108. PubMed ID: 29064651 [TBL] [Abstract][Full Text] [Related]
18. Percutaneous tibial nerve stimulation versus electrical stimulation with pelvic floor muscle training for overactive bladder syndrome in women: results of a randomized controlled study. Scaldazza CV; Morosetti C; Giampieretti R; Lorenzetti R; Baroni M Int Braz J Urol; 2017; 43(1):121-126. PubMed ID: 28124534 [TBL] [Abstract][Full Text] [Related]
19. Effects of Transcutaneous and Percutaneous Tibial Nerve Stimulation in Bosnian Female Patients with an Idiopathic Overactive Urinary Bladder. Zonić-Imamović M; Sinanović O; Imamović M; Muftić M; Janković S; Bazardžanović M Acta Med Acad; 2021 Aug; 50(2):235-243. PubMed ID: 34847676 [TBL] [Abstract][Full Text] [Related]
20. Outcomes following percutaneous tibial nerve stimulation (PTNS) treatment for neurogenic and idiopathic overactive bladder. Tudor KI; Seth JH; Liechti MD; Ochulor J; Gonzales G; Haslam C; Fox Z; Pakzad M; Panicker JN Clin Auton Res; 2020 Feb; 30(1):61-67. PubMed ID: 30074101 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]